GlaxoSmithKline Pakistan Limited Stock price

Equities

GLAXO

PK0001301016

Pharmaceuticals

End-of-day quote Pakistan S.E. 07:00:00 2024-03-17 pm EDT 5-day change 1st Jan Change
84.94 PKR +0.76% Intraday chart for GlaxoSmithKline Pakistan Limited -2.20% +2.35%
Sales 2021 36.66B 132M Sales 2022 41.84B 150M Capitalization 27.95B 100M
Net income 2021 5.35B 19.21M Net income 2022 2.46B 8.84M EV / Sales 2021 0.96 x
Net cash position 2021 8.43B 30.24M Net cash position 2022 4.41B 15.82M EV / Sales 2022 0.56 x
P/E ratio 2021
8.12 x
P/E ratio 2022
11.3 x
Employees 1,768
Yield 2021
5.13%
Yield 2022
-
Free-Float 14.14%
More Fundamentals * Assessed data
Dynamic Chart
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Glaxosmithkline Pakistan Limited Announces Change of Company Secretary CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
GlaxoSmithKline Pakistan Limited Announces Board Changes CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Glaxosmithkline Pakistan Limited Appoints Simon Forster as Director CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Glaxo Smith Kline Pakistan Limited Appoints Lai Kuen Goh as Director CI
GlaxoSmithKline Pakistan Limited Announces Board Changes CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Glaxosmithkline Pakistan Limited Announces Board Changes CI
More news
1 day+0.76%
1 week-2.20%
Current month-2.06%
1 month+8.34%
3 months-3.63%
6 months+19.65%
Current year+2.35%
More quotes
1 week
81.25
Extreme 81.25
86.01
1 month
80.99
Extreme 80.99
94.98
Current year
77.00
Extreme 77
94.98
1 year
68.00
Extreme 68
97.50
3 years
68.00
Extreme 68
173.50
5 years
68.00
Extreme 68
203.80
10 years
68.00
Extreme 68
274.47
More quotes
Managers TitleAgeSince
Chief Executive Officer - 20-02-29
Director of Finance/CFO - 21-05-31
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 70 20-04-01
Director/Board Member - 18-12-04
Chief Executive Officer - 20-02-29
More insiders
Date Price Change Volume
24-03-18 84.94 +0.76% 7,000
24-03-15 84.3 -0.89% 6,000
24-03-14 85.06 +2.42% 57,000
24-03-13 83.05 -3.43% 20,000
24-03-12 86 -0.98% 10,000

End-of-day quote Pakistan S.E., March 17, 2024

More quotes
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, including but not limited to psoriasis, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
More about the company
  1. Stock
  2. Equities
  3. Stock GlaxoSmithKline Pakistan Limited - Pakistan S.E.